Real-life effectiveness and safety of lebrikizumab in older patients with atopic dermatitis: a multicentre study

Lebrikizumab, a monoclonal antibody targeting interleukin-13, has demonstrated efficacy and safety in adults with moder- ate-to-severe atopic dermatitis (AD), but data for older patients remain limited. We conducted a retrospective multicentre study including 90 patients aged ≥ 60 years with moderate-to-severe AD treated with lebrikizumab across 23 Italian dermatol- ogy centres. Clinical outcomes were assessed at baseline and at weeks (W) 16, 24 and 52. Mean (SD) Eczema Area and Severity Index (EASI) decreased from 23.24 (7.93) at baseline to 6.33 (6.54) at W16, 3.57 (3.74) at W24 and 2.70 (4.83) at W52 (P<0.0001). EASI 75 (75% improvement from baseline) was achieved by 58%, 82% and 87% of patients at W16, W24 and W52, respectively. Clinical responses were similar across age groups and independent of prior biologic or Janus kinase inhibitor exposure. Adverse events occurred in 8% of patients and were mainly mild. These findings support the effectiveness and safety of leb- rikizumab in older patients with AD in real-world clinical practice.